Octagon Capital invests in public and private healthcare companies globally. We strive to build long-term investments and partner with our portfolio companies to support innovation. Octagon manages capital on behalf of global institutions including university endowments, non-profit foundations, family offices, pension funds and established asset managers.

Private Portfolio

  • 4D Molecular Therapeutics

    4D Molecular Therapeutics

    4DMT is a gene therapy company with a transformative discovery platform that enables its “disease first” approach to product discovery and development.

  • Everest Medicines

    Everest Medicines

    Everest Medicines (SEHK: 1952.HK) is a late clinical-stage biopharmaceutical company focused on licensing, developing and commercializing globally innovative therapies.

  • Harbour BioMed

    Harbour BioMed

    Harbour BioMed is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and immunological diseases.

  • New Horizon

    New Horizon

    New Horizon Health is a leader and a pioneer in home testing for a number of different types of cancers and is China’s first biotech company focusing on early cancer screening.

  • NiKang Therapeutics

    NiKang Therapeutics

    NiKang Therapeutics is an early stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs.

  • Taysha Gene Therapies

    Taysha Gene Therapies

    Taysha Gene Therapies (NASDAQ: TSHA) is a patient-centric gene therapy company with a mission to eradicate monogenic CNS disease.

  • Sonoma Biotherapeutics

    Sonoma Biotherapeutics

    Sonoma Biotherapeutics is leading the development of adoptive T-cell (Treg) therapies for autoimmune and degenerative diseases.

IPO Cornerstone Portfolio*

  • Antengene Corporation Limited

    Antengene Co. Ltd

    Antengene (SEHK: 6996.HK) is a biotech company with synergistic first-in-class, only-in-class and best-in-class cancer therapies that unlock the full therapeutic potential of its drug candidates.

  • Everest Medicines

    Everest Medicines

    Everest Medicines (SEHK: 1952.HK) is a late clinical-stage biopharmaceutical company focused on licensing, developing and commercializing globally innovative therapies.

  • InnoCare Pharma Limited

    InnoCare Pharma Limited

    InnoCare (SEHK: 9969.HK) is a biopharmaceutical company rooted in China with the global vision to discover and develop novel treatment for cancer and autoimmune diseases.

  • OcuMension Therapeutics

    OcuMension Therapeutics

    Ocumension Therapeutics (SEHK: 1477.HK) is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies.

  • Peijia Medical Limited

    Peijia Medical Limited

    Peijia Medical Limited (SEHK: 9996.HK) aims to become a world-renowned medical device platform that provides total treatment solutions for structural heart and neurovascular diseases.

  • RemeGen Co. Ltd

    RemeGen Co. Ltd

    RemeGen (SEHK: 9995.HK) is a biopharmaceutical company focused on the treatment of autoimmune, oncology and ophthalmic diseases with unmet needs in China and globally.

Founder

Ting Jia (TJ)

Dr. Ting Jia, Ph.D., also known as TJ, is the Founder of Octagon Capital and has served as the firm’s Chief Investment Officer since 2019. Prior to founding Octagon Capital, TJ served as Managing Director at Hillhouse Capital Management. Before this, TJ was an investment analyst at BVF Partners and a management consultant at McKinsey’s New York office. TJ started his career as a research fellow at memorial Sloan-Kettering Cancer Center. He received his Ph.D. in Immunology from Cornell University Weill Medical College and a B.S. with first honor in Biological Sciences from Sun Yat-sen University.

Careers

We are always looking for exceptional and talented people to join the team at Octagon Capital. We believe the opportunity to work alongside our team members that share core values in intellectual curiosity, humility and integrity would be both challenging and rewarding. If you are interested in joining the Octagon Capital team, please submit your resume at careers@octagoninvest.com

 

Contact Us

+1-212-369-2829

654 Madison Ave, 16th Floor
New York, NY 10065